Did you mean?

J B Chemicals & Pharmaceuticals Ltd pe ratio

IOL Chemicals & Pharmaceuticals Ltd pe ratio

Biofil Chemicals & Pharmaceuticals Ltd pe ratio

Home

Insights

J B Chemicals & Pharmaceuticals Ltd P/E Ratio

J B Chemicals & Pharmaceuticals Ltd P/E Ratio

download
stocks purchased

₹ 0.5 Cr

Volume transacted

stocks purchased

2.5 K

stocks traded

Image

J B Chemicals & Pharmaceuticals Ltd

NSE: JBCHEPHARM

PE

50.9

Last updated : 20 Jun 05:23 AM

Key Highlights

    The P/E Ratio of J B Chemicals & Pharmaceuticals Ltd is 50.9 as of 20 Jun 05:23 AM .a1#The P/E Ratio of J B Chemicals & Pharmaceuticals Ltd changed from 14.9 on March 2019 to 37.2 on March 2023 . This represents a CAGR of 20.08% over 5 years. a1#The Latest Trading Price of J B Chemicals & Pharmaceuticals Ltd is ₹ 1831 as of 20 Jun 10:46 .a1#The PE Ratio of Pharmaceuticals Industry has changed from 28.7 to 27.7 in 5 years. This represents a CAGR of -0.71%a1# The PE Ratio of Automobile industry is 11.3. The PE Ratio of Finance industry is 31.6. The PE Ratio of IT - Software industry is 28.9. The PE Ratio of Pharmaceuticals industry is 101.4. The PE Ratio of Retail industry is 142.7. The PE Ratio of Textiles industry is 7.2. In 2024a1#The Market Cap of J B Chemicals & Pharmaceuticals Ltd changed from ₹ 2885 crore on March 2019 to ₹ 15250 crore on March 2023 . This represents a CAGR of 39.51% over 5 years. a1#The Revenue of J B Chemicals & Pharmaceuticals Ltd changed from ₹ 785.7 crore to ₹ 878.36 crore over 8 quarters. This represents a CAGR of 5.73% a1#The EBITDA of J B Chemicals & Pharmaceuticals Ltd changed from ₹ 173.65 crore to ₹ 214.75 crore over 8 quarters. This represents a CAGR of 11.21% a1#The Net Profit of J B Chemicals & Pharmaceuticals Ltd changed from ₹ 105.2 crore to ₹ 126.16 crore over 8 quarters. This represents a CAGR of 9.51% a1#The Dividend Payout of J B Chemicals & Pharmaceuticals Ltd changed from 22.04 % on March 2019 to 35.33 % on March 2023 . This represents a CAGR of 9.90% over 5 years. a1#

Open Demat Account

Lead form image

+91

50 Years

of Trust & Legacy

₹0 AMC

for First Year

₹0 Brokerage

on Delivery, Intraday, Currency and NSE F&O

*By signing up you agree to our terms & conditions

×

P/E Ratio Over Time

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share. P/E Ratio Formula P/E ratio = (CMP of share/ Earning per share) Types of Price to Earning Ratio 1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance. 2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

P/E Ratio Over Time

Period
Mar '1914.9
Mar '2014.4
Mar '2121.6
Mar '2231.6
Mar '2337.2

Fundamental Metrics

Market Cap

28,127 Cr

EPS

35.6

P/E Ratio (TTM) *

50.9

P/B Ratio (TTM) *

9.6

Day’s High

1840.45

Day’s Low

1780.05

DTE *

0.1

ROE *

18.9

52 Week High

1935.0

52 Week Low

1131.08

ROCE *

24.1

* All values are consolidated

Last Updated time: 20 Jun 05:23 AM

* All values are consolidated

Last Updated time: 20 Jun 05:23 AM

Image

J B Chemicals & Pharmaceuticals Ltd

NSE: JBCHEPHARM

PRICE

1831.75

19.55 (1.08%)

stock direction

Last updated : 20 Jun 10:46

×

PRICE

The current market price or CMP refers to the price at which the securities are trading in the share market. Current price in Over-the-counter costs: The following current price depends upon the bid price & the asking price when a financial asset is sold over-the-counter(OTC). Current Price in Bond Market: The current price of a bond is determined by measuring the actual interest rate against the bid-related interest rate. The par or the face value is then calculated to represent the remaining interest payments due which occur before the maturity of the bond.

Share price Over Time

1M

1Y

3Y

5Y

* All values are in Rupees

SWOT Analysis Of J B Chemicals & Pharmaceuticals Ltd

Strength

4

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

BlinkX Score for J B Chemicals & Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

Asset Value vs Market Value

Market Value

28,128

Asset Value

1,354

19.8 X

Value addition

* All values are in Rupees

PE Ratio Over Market Cap

Company NamePEMarket Cap (INR Cr.)
Sun Pharmaceuticals Industries Ltd36360,896
Cipla Ltd29125,905
Divis Laboratories Ltd74118,864
Zydus Lifesciences Ltd28108,024
Dr Reddys Laboratories Ltd1799,341
J B Chemicals & Pharmaceuticals Ltd5028,127

Key Valuation Metric

Earnings

552 Cr

50.9 X

PE Ratio

Market Cap

₹28127Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

PE Ratio

PS Ratio

PB Ratio

Earnings

552 Cr

50.9 X

PE Ratio

Market Cap

₹28127Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

×

Market Cap Over Time

Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore

Market Cap Over Time

Period
Mar '192885
Mar '203929
Mar '219688
Mar '2212173
Mar '2315250

* All values are a in crore

×

Revenue Over Time

Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services. Types of Revenue: 1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered. 2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees. Formula for Revenue: The formula for calculating revenue is based on two goods & services: For goods: Revenue = Avg unit price x Number of Units sold For services: Revenue = Avg unit price x Number of Customers served.

Revenue Over Time

Period
Jun '22786
Sep '22811
Dec '22796
Mar '23767
Jun '23902
Sep '23889
Dec '23852
Mar '24878

* All values are a in crore

×

EBITDA Over Time

PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.

EBITDA Over Time

Period
Jun '22174
Sep '22186
Dec '22178
Mar '23168
Jun '23238
Sep '23251
Dec '23230
Mar '24215

* All values are a in crore

×

Net Profit Over Time

Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions. Net Profit formula is expressed as: Net Profit = Total Revenue - Total Expense Net Profit Margin Ratio: Net Profit Margin Ratio = Net Profit / Total Revenue

Net Profit Over Time

Period
Jun '22105
Sep '22111
Dec '22106
Mar '2388
Jun '23142
Sep '23151
Dec '23134
Mar '24126

* All values are a in crore

×

Dividend Payout Over Time

Dividend payout refers to the total dividends paid to shareholders relative to the company's earnings. It is a financial measure that determines the percentage of earnings paid out to existing shareholders as dividends. How to calculate Dividend Payout Ratio? The dividend payout ratio formula is as follows: DPR = Dividends paid / Net earnings With the dividend payout ratio, you can understand the company's priorities. It is an important metric that allows you to easily check DPR online.

Dividend Payout Over Time

Period
Mar '1922
Mar '2032
Mar '2129
Mar '2235
Mar '2335

* All values are a in %

About J B Chemicals & Pharmaceuticals Ltd

About J B Chemicals & Pharmaceuticals Ltd

    J B Chemicals & Pharmaceuticals (JBC) was originally promoted and incorporated in Maharashtra by J B Mody as J B Mody Chemicals & Pharmaceuticals in December 18th, 1976. The Company is engaged in the business of manufacturing and marketing of diverse range of pharmaceuticals formulations, herbal remedies and APIs. The company has manufacturing units at Thane, Belapur, Ankleshwar, Panoli and Daman. The bulk drug plant at Panoli and formulation plant at Daman became operational in Apr.'95. Products like metrogyl, rantac (a ranitidine-based formulation), and nicardia (a cardiac care medicine) form a significant part of the company's sales. JBC has its subsidiaries namely Lekar Healthcare Ltd and J.B Life Science Overseas Ltd. JBC had a tie-up with Justesa Imagen, Spain, to manufacture and market radio diagnostics under the Trazograf brand name. JBC has also diversified into high-growth agro-based products by acquiring McDa Agro (MAL). The products manufactured by MAL complement fertilisers and increase crop productivity. It has entered into a MoU with GNFC to distribute these products locally. The pharmaceutical divisions of Ifiunik Pharmaceuticals and Unique Pharmaceutical Laboratories has been merged into the company with effect from April 2000. Unique Chemicals (A Division of the company) manufacturing and marketing Bulk Drugs has been awarded Certificate of Suitability to Europeon Pharmacopoeia Monograph for Nifedipine EP from Europeon Directorate for the Quality Medicines. In Feb. 2002 the company has achieved another break through in its major R & D Activity - Invention biologically active molecules - New Chemical Entity. In 2001-02 the company introduced 3 products Reducin XX and two in the Cholesterol reducing segment i.e., Ifistatin and Vasolip. The company has launched five new products during the year 2003-04 in the global markets to widen its product portfolio. During 2004-05, the company launched new products Cephalosporins, Moviz and its expansion Movi 3D and a nueropsychiatry product through Zephyr for the first time. A 100% EOU manufacturing facility at Panoli for production of Gel, Ointment was commissioned during 2001-02 at a cost of Rs.21 crores and the same was financed through internal accruals. To manufacture 'DOKTOR MOM' lozenges the company is setting up two manufacturing units at Daman at a capital outlay of Rs.28 crores, which is to be financed through internal accruals. The commercial production of the Doktor Mom lozenges at its 100% Export Oriented Unit, started from 1 Sep. 2003 and tablets from 1, Jan. 2004 in Daman.Doktor Mom', the company's brand,was adjudged the Most Trusted European Brand by Reader's Digest in the cold and cough segment for the fourth consecutive year in 2003-04. During 2004-05, the company received approval for its pharmaceutical manufacturing unit from TGA (Australia). During 2004-05, the company plants were approved by US-FDA, TGA-Australia, EDQM, MCC-South Africa, INVIMA (Colombia) and MHRA (UK). During 2004-05, the company is setting up a new facility conforming to international standards in Panoli (Gujarat) to manufacture contrast media products by June 2006. During 2004-05, the company has planned to set up a wholly owned subsidiary in Moscow, Russia, called 'Unique Pharmaceuticals Laboratories' with the initial investment of $ 3 million. During 2005, the company entered into two agreements, one with Pharma-a-Care Pharmaceuticals Pte. Ltd., in Australia to develop its niche products in Australian market and another with Ranbaxy Laboratories to enter in the Romanian market. The company has subdivided the value of the share from Rs.10/- per share to Rs.2/- per share with effective from 05, April 2005. During 2005-2006, the company has proposed to amalgamate its wholly owned subsidiary viz. lekar healthcare ltd with itself. The company has fixed April 1, 2006 as the appointed date. During the year 2015, J.B. Chemicals & Pharmaceuticals Private Limited, Singapore, ceased to be the company's subsidiary consequent to its dissolution. The Scheme of Amalgamation and Arrangement between Jyotindra Mody Holdings Private Limited and Ansuya Mody Securities Private Limited and Dinesh Mody Securities Private Limited and Kumud Mody Securities Private Limited and Shirish B. Mody Investments Private Limited and Bharati S. Mody Investments Private Limited (Transferor Companies) and J. B. Chemicals & Pharmaceuticals Limited (Transferee Company) and their respective shareholders under Sections 391 to 394 read with Sections 100 to 103 of the Companies Act, 1956 and Section 55 of the Companies Act, 2013 and any other applicable provisions of the Companies Act, 1956 and the Companies Act, 2013, which was approved by the Board on 15 April 2014 and members of the company at Court Convened Meeting held on 14 October 2014 and public shareholders through postal ballot and e-voting on 16 October 2014, was sanctioned by the Hon'ble Bombay High Court on 27 February 2015. The Scheme has become effective on 13 April 2015 with appointed date of 1 April 2014. Accordingly, the Transferor Companies stand merged with the company and the merger has been given effect to in the financial statements of the company for the year ended on March 31, 2015. Consequently, 4,33,42,270 equity shares of FY Rs. 2 held by the Transferor Companies in the company have been cancelled and the company has allotted 4,33,42,270 equity shares of Rs. 2 each credited as fully paid up to the shareholders of the Transferor Companies in accordance with the fair share entitlement ratio specified in the Scheme. During the year 2016, the Company's subsidiary Unique Pharmaceutical Laboratories FZE (UPL FZE) acquired 2, 194,030 Ordinary Shares in Biotech Laboratories (Pty.) Ltd. from Afrika Biopharma Investments (Pty). Ltd. Consequent to restructuring of existing 49% shareholding in Biotech and issue of certain shares by Biotech after the aforesaid acquisition, UPL FZE now holds 95.24% voting capital of Biotech. Accordingly, Biotech has become subsidiary of the Company. Subsequently, the Company's subsidiary J.B. Healthcare Pvt. Ltd., Jersey, has been dissolved. With a view to return surplus cash and pursuant to authority conferred under the Articles of Association of the Company, the Board approved buy-back of fully paid up equity shares of face value of Rs 2 by the Company up to 12,50,000 equity shares at a price of Rs 400 per equity share for a total consideration not exceeding Rs 5,000 lakhs (buy-back amount) excluding transaction costs, on proportionate basis through tender offer. The number of equity shares authorized for buy-back represents 1.47% of the total outstanding equity shares, while the buy-back amount represents 3.85% of the equity share capital and free reserves as at March 31, 2017. This buy-back will be implemented in accordance with provisions of the Companies Act, 2013 and Securities and Exchange Board of India (Buy-back of Securities) Regulations, 1998. The Company completed on 25 July 2017 buy-back of 1,250,000 equity shares of face of Rs. 2 at price of Rs. 400 per share on proportionate basis through tender offer in accordance with provisions of the Companies Act, 2013 and Securities and Exchange Board of India (Buy-back of Securities) Regulations, 1998. Consequently, the paid-up equity share capital stands reduced to 83,569,975 equity shares of Rs. 2. The Company has transferred the sum of Rs. 25 lakhs from general reserves to capital redemption reserve account pursuant to Section 69 of the Companies Act, 2013. The Company launched four new products in dermatology, amoebicide and probiotic segments during the year 2018. The Company completed on 1st November 2018 buy-back of 3,333,333 equity shares of face value of Rs 2 at price of Rs 390 per share on proportionate basis through tender offer in accordance with provisions of the Companies Act, 2013 and Securities and Exchange Board of India (Buy-back of Securities) Regulations, 1998. Consequently, the paid-up equity share capital stands reduced to 80,236,642 equity shares of Rs 2. The Company has transferred the sum of Rs 66.67 lakhs from general reserve to capital redemption reserve account pursuant to Section 69 of the Companies Act, 2013. The Company launched six new products during the year 2020 across Cardiac and Gastrointestinal (GI) segments. On 2nd July, 2020, a Share Purchase Agreement was signed between founder, Mody Family members and Tau Investment Holdings Pte. Ltd., Singapore, an affiliate of global private equity firm KKR, where Tau Investment Holdings Pte. Ltd. acquired controlling stake of 41,731,363 (54%) equity shares of Rs. 2 each in the Company (JB Chemcials Pharmaceuticals Limited) from Mody Family members. Following execution of the above referred Share Purchase Agreement to acquire shares in and control over the Company, Tau Investment Holdings Pte. Ltd. and persons acting in concert made an open offer for acquiring 26% stake from public shareholders of the Company. In FY 2021, the Company introduced newer therapeutic categories for Diabetes, Nephrology, Respiratory and Virology. It launched 10 new products across angiotensin receptor blocker, anti-diabetic, calcium channel blocker, hypotensive, anti-peptic ulcerant, anti-viral and anti-parasitic segments. During the year 2022-23, the Company launched 17 new products in FY233 in the field of Gastro Intestinal, Gynaecology, Respiratory and Anti Diabetes. It acquired the Azmarda' brand from Novartis, a niche Paediatric portfolio from Dr Reddy and the Razel' franchise from Glenmark.

J B Chemicals & Pharmaceuticals Ltd News Hub

News

J B Chemicals & Pharmaceuticals Ltd up for fifth session

J B Chemicals & Pharmaceuticals Ltd is up for a fifth straight session in a row. The stock...

Read more

13 Jun 202413:00

News

J B Chemicals & Pharmaceuticals allots 11,582 equity shares under ESOS

J B Chemicals & Pharmaceuticals has allotted 11,582 equity shares under ESOS on 04 June 20...

Read more

04 Jun 202419:00

News

Board of J B Chemicals & Pharmaceuticals recommends appointment of director

The Board of J B Chemicals & Pharmaceuticals at its meeting held on 03 June 2024 has recom...

Read more

03 Jun 202413:32

News

Board of J B Chemicals & Pharmaceuticals recommends final dividend

J B Chemicals & Pharmaceuticals announced that the Board of Directors of the Company at it...

Read more

18 May 202409:31

News

J B Chemicals & Pharmaceuticals announces board meeting date

J B Chemicals & Pharmaceuticals will hold a meeting of the Board of Directors of the Compa...

Read more

11 May 202412:06

News

J B Chemicals & Pharmaceuticals Ltd gains for third consecutive session

J B Chemicals & Pharmaceuticals Ltd gained for a third straight session today. The stock i...

Read more

12 Apr 202413:05

Product Composition by Percentage (Revenue)

Document

Annual Reports

Annual Report 2023

dropdown
download

Credit Ratings

Credit Report 2023

dropdown
download

Concalls

Jan 2023

PPT

Mar 2021

PPT

Feb 2021

PPT

Nov 2020

PPT

June 2020

PPT

Feb 2020

PPT

Jan 2023

PPT

Mar 2021

PPT

Feb 2021

PPT

Nov 2020

PPT

June 2020

PPT

Feb 2020

PPT

FAQs for PE of J B Chemicals & Pharmaceuticals Ltd

What is J B Chemicals & Pharmaceuticals Ltd current share price?

The current market price of J B Chemicals & Pharmaceuticals Ltd as of June 20, 2024 is ₹1831.75.

Is J B Chemicals & Pharmaceuticals Ltd a good investment?

As per BlinkX Score J B Chemicals & Pharmaceuticals Ltd scores 60 in Revenue, 53 in Profitability. However it's advisable to conduct comprehensive research or seek advice from experts to evaluate whether it aligns with your investment objectives.

What are J B Chemicals & Pharmaceuticals Ltd's total net assets?

According to J B Chemicals & Pharmaceuticals Ltd's most recent financial filings, the company's net assets total ₹1353.6 Cr.

Is J B Chemicals & Pharmaceuticals Ltd making a profit or loss?

J B Chemicals & Pharmaceuticals Ltd's net Profit as of June 20, 2024 is close to ₹552 Cr.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199